作者:Per Sauerberg、Jens Jorgen Larsen、Erik Falch、Povl Krogsgaard-Larsen
DOI:10.1021/jm00156a018
日期:1986.6
A series of conformationally restricted compounds containing the 4,5,6,7-tetrahydroisoxazolo[4,5-c]pyridin-3-ol (THPO) skeleton, including O-methyl-THPO (10a) and O,5-dimethyl-THPO (11a), were synthesized. The compounds were designed by bioisosteric replacement of the methyl ester groups of the muscarinic cholinergic agonists norarecoline and arecoline by the 3-methoxyisoxazole group, and their interactions
一系列包含4,5,6,7-四氢异恶唑并[4,5-c]吡啶-3-醇(THPO)骨架的构象受限化合物,包括O-甲基-THPO(10a)和O,5-二甲基-合成了THPO(11a)。这些化合物是通过3-甲氧基异恶唑基团对毒蕈碱型胆碱能激动剂去甲arecoline和槟榔碱的甲基等位生物置换而设计的,并在体外测试了它们与中毒和外周毒蕈碱受体的相互作用。化合物10a,11a,O-乙基-THPO(10b),O-炔丙基-THPO(10j)和O-乙基-5-甲基-THPO(11b)是毒蕈碱芥子[3H] PrBCM结合的抑制剂增强大鼠脑膜的效力。但是,有 这些结合数据与化合物对外周(回肠)毒蕈碱受体的影响之间的相关度非常低,其中11a,10j,11b和10a是激动剂,效力递减顺序,而O-异丙基-THPO(10e )表现出拮抗作用。化合物的相对较低的pKa值(对于具有仲氨基的化合物为7.5-7.7,对于具有叔氨基的化合物为6